The estimated Net Worth of Terry Vance is at least $541 Thousand dollars as of 13 December 2023. Mr. Vance owns over 15,295 units of Enanta Pharmaceuticals Inc stock worth over $69,832 and over the last 12 years he sold ENTA stock worth over $139,490. In addition, he makes $331,997 as Independent Director at Enanta Pharmaceuticals Inc.
Terry has made over 4 trades of the Enanta Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 15,295 units of ENTA stock worth $139,490 on 13 December 2023.
The largest trade he's ever made was selling 15,295 units of Enanta Pharmaceuticals Inc stock on 13 December 2023 worth over $139,490. On average, Terry trades about 2,274 units every 245 days since 2013. As of 13 December 2023 he still owns at least 5,800 units of Enanta Pharmaceuticals Inc stock.
You can see the complete history of Mr. Vance stock trades at the bottom of the page.
Terry C. Vance is Independent Director of the Company. From June 2013 until November 2018, Mr. Vance was Chief Business Officer of BioMotiv, LLC, a drug development company affiliated with The Harrington Project. Until January 2018, Mr. Vance was a Managing Member of EGS Healthcare, a late-stage venture capital fund that he co-founded in 2000. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotechnology companies. Prior to Eagle, Mr. Vance was an investment banker, first with Salomon Brothers and then with Goldman Sachs, where he was a vice president in the Capital Markets Division. Mr. Vance received an AB from Princeton University and an MBA from Stanford University.
As the Independent Director of Enanta Pharmaceuticals Inc, the total compensation of Terry Vance at Enanta Pharmaceuticals Inc is $331,997. There are 11 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of $4,483,500.
Terry Vance is 63, he's been the Independent Director of Enanta Pharmaceuticals Inc since 2011. There are 8 older and 6 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.
Terry's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., and Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.
enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.
Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include: